OvaScience to Present at Cowen and Company Health Care Conference

07 Mar 2016, 00:00 AM EST

WALTHAM, Mass.–(BUSINESS WIRE)–OvaScience^SM (NASDAQ:OVAS), a global fertility company
focused on the discovery, development and commercialization of new
treatment options, announced today that Company management will present
at the Cowen and Company 36^th Annual Health Care Conference
on Wednesday, March 9, 2016 at 8:00 a.m. ET at the Boston Marriott
Copley Place in Boston, MA.

A live audio webcast of the presentation can be accessed by visiting the
Investors section of the Company’s website at www.ovascience.com.
A replay of the webcast will be archived on the OvaScience website for
two weeks following the presentation.

About OvaScience

OvaScience (NASDAQ: OVAS) is a global fertility company dedicated to
improving treatment options for women around the world. OvaScience is
discovering, developing and commercializing new fertility treatments
because we believe women deserve more options. Each OvaScience treatment
is based on the Company’s proprietary technology platform that leverages
the breakthrough discovery of egg precursor (EggPC^SM) cells –
immature egg cells found inside the protective ovarian lining. The
AUGMENT^SM treatment, a fertility option specifically designed
to improve egg health, is available in certain IVF clinics in select
international regions. OvaScience has commenced a non-commercial
preceptorship training program with the OvaPrime^SM treatment,
which could increase a woman’s egg reserve, and is developing the OvaTure^SM treatment,
a potential next-generation IVF treatment that could help a woman
produce healthy, young, fertilizable eggs without hormone injections.
OvaScience treatments are not available in the U.S. For more
information, please visit www.ovascience.com
and www.augmenttreatment.com
and connect with us on Twitter
and Facebook.

Forward-Looking Statements

This press release includes forward-looking statements about the
Company’s plans for the AUGMENT treatment, OvaPrime treatment and
OvaTure treatment. Actual results may differ materially from those
indicated by these forward-looking statements as a result of various
important factors, including risks related to: the possibility
that international IVF clinics that we work with may determine not to
provide or continue providing the AUGMENT treatment, or to delay
such treatment based on clinical efficacy, safety or commercial,
logistic, regulatory or other reasons; the science underlying our
treatments (including the AUGMENT, OvaPrime and OvaTure treatments),
which is unproven; our ability to obtain regulatory approval or licenses
where necessary for our treatments; our ability to develop our
treatments on the timelines we expect, if at all; our ability to
commercialize our treatments, on the timelines we expect, if at all; as
well as those risks more fully discussed in the “Risk Factors” section
of our most recently filed Quarterly Report on Form 10-Q and/or Annual
Report on Form 10-K. The forward-looking statements contained in this
press release reflect our current views with respect to future events.
We anticipate that subsequent events and developments will cause our
views to change. However, while we may elect to update these
forward-looking statements in the future, we specifically disclaim any
obligation to do so. These forward-looking statements should not be
relied upon as representing our view as of any date subsequent to the
date hereof.